Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03279250 · ClinicalTrials.gov registry record · Phase 2
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT03279250: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03279250 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03279250, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery. Apalutamide and abiraterone acetate may stop the growth of cancer cells either by killing the cells or by blocking some of the enzymes needed for cell growth. Hormone therapy, using gonadotropin-releasing hormone analog, may fight prostate cancer by lowering the amount of testosterone the body makes. Giving apalutamide, gonadotropin-releasing hormone analog, and abiraterone acetate may work better in treating participants with prostate cancer.
Interventions
- DRUG Apalutamide
- PROCEDURE Radical Prostatectomy
- DRUG Prednisone
- DRUG Abiraterone Acetate
- BIOLOGICAL Gonadotropin-releasing Hormone Analog
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2017-10-13 |
| Est. Completion | 2021-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03279250
The ClinicalTrials.gov registry entry for NCT03279250 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Apalutamide is the first listed.
NCT03279250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03279250 about?
NCT03279250 is a clinical study titled "Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer". This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery. Apalutamide and abiraterone acetate may stop the growth of cancer cells either by killing the cells or b...
What is the current status of trial NCT03279250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2017-10-13. Estimated completion is 2021-05-11.
What interventions are being tested in trial NCT03279250?
The interventions under investigation include: Apalutamide (DRUG), Radical Prostatectomy (PROCEDURE), Prednisone (DRUG), Abiraterone Acetate (DRUG), Gonadotropin-releasing Hormone Analog (BIOLOGICAL).
Who is sponsoring clinical trial NCT03279250?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.